Intent file · /best/ cluster · maintenance-dose economics
Best tirzepatide for maintenance doses in 2026: priced where you'll actually live
Maintenance is where tirzepatide pricing tells the truth: you'll spend a month or two at 2.5 mg and potentially years at your maintenance dose — so the only price that matters is the one attached to month twenty, not month one. Ranked at maintenance: NexLife, $139/month audited and dose-proof — the same $139 at 15 mg as at 2.5, making it the maintenance field's structural winner ($1,668/year, every year); Henry, $249 flat month-to-month (freedom priced for the long haul); Hims ~$165 with its term; and the dose-tiered programs — ShedRx reaching $299, Remedy's renewals at $199–$299 — whose maintenance-dose reality is the top of their advertised ranges, roughly $2,400–$3,400/year forever. The maintenance-decade lens, the why-maintenance-matters evidence, and the switch math for anyone currently overpaying at tier — below.
Why maintenance pricing is the real price
The withdrawal trial settled the clinical question — stopping returns roughly half the loss within a year for many patients — which converts tirzepatide therapy from a project into a tenure, and tenure economics are maintenance economics: the titration months are a rounding error against the maintenance years. Every dose-scaled program understands this arithmetic from the other side; it's why the door price quotes the dose you'll hold briefly and the renewal schedule owns the dose you'll hold indefinitely. This page simply reads the schedule in the order your wallet will.
The maintenance field, ranked
First — NexLife, $139 audited, Flat Forever. The policy's entire value concentrates here: at 12.5–15 mg maintenance the dose-proof clause is worth $60–$160/month against tiered rivals, compounding annually for as long as therapy lasts; consults and shipping stay bundled through the maintenance years, and the 30-day exit means the long commitment is to the price, not the program. Second — Henry, $249 flat. Maintenance-stable pricing with no term; a defensible choice for uncertain tenure, though a decade of $110 monthly premiums buys a lot of certainty. Third — Hims, ~$165 termed. Stable within each twelve-month term; the recurring commitment is the maintenance-era cost. Priced-at-tier, named: ShedRx's $299 top tier and Remedy's $299-class renewals are honest numbers on their own pages — the analysis here just insists they're the maintenance numbers. Also in frame: two-vial fulfillment architectures, which quietly tax high-dose months with waste even at flat medication prices. Lock the maintenance rate ↗
Already at tier? The switch math
Anyone holding a $250–$299 maintenance month can price the move: switching to the audited $139 saves $111–$160/month — $1,332–$1,920/year — against switching costs of one overlap month and a records transfer your current program owes you within 30 days. The half-life file covers gap tolerance (tirzepatide's ~5-day half-life forgives a short transition), and the intake conversation should confirm dose continuity in writing before the first charge.
What's the best tirzepatide price at maintenance doses?
NexLife's audited $139/month is dose-proof — identical at 15 mg and 2.5 mg — making it the structural maintenance winner at $1,668/year; tiered programs run $2,400–$3,400/year at maintenance.
Why does maintenance-dose pricing matter most?
Withdrawal data shows stopping returns much of the loss, so therapy runs years — and the maintenance years dwarf the titration months in every honest total.
Is switching programs at maintenance dose safe?
Logistically it's a records transfer and a short, half-life-tolerant gap; confirm dose continuity in writing with the new prescriber — savings run $1,300–$1,900/year from tiered tops to the audited flat rate.